Alector, GSK Team Up to Develop 2 Antibody Treatments for ALS

Alector, GSK Team Up to Develop 2 Antibody Treatments for ALS

298512

Alector, GSK Team Up to Develop 2 Antibody Treatments for ALS

Alector and GlaxoSmithKline (GSK) have established a partnership to develop two investigational antibodies — called AL001 and AL101 — to boost the production of the progranulin protein as a potential treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Low levels of progranulin, known as PGRN, which is a key regulator of immune responses and nerve cell survival in the brain, have been associated with ALS and other disorders. A Phase 2 study of AL001 in…

You must be logged in to read/download the full post.